 Times of India |
Low-fat meals cuts gall stone risk
Times of India The formation of gallstones starts with bile, a fluid composed mostly of water, bile salts, lecithin and cholesterol, produced in the liver to digest fat. Most of it is stored in the gallbladder, a four-inch sac that sits under the liver, until it’s … |
 Economic Times |
Bayer to appeal against India’s patent ruling on Nexavar
Business Line The IPAB also came to the conclusion that even though Bayer had obtained a patent for Nexavar in India in 2008, it could not make available the kidney and liver cancer drug on a large scale at an affordable price within the stipulated time. Rejecting … Patients win over patentsThe Hindu Bayer fails to overturn Nexavar compulsory licence in IndiaPMLiVE India board rules against Bayer in cancer drug patent caseMedCity News Fox Business –China Post all 60 news articles » |
Siliconindia.comSachin Tendulkar Launches Cancer Research CentreSiliconindia.comBangalore: The master blaster, cricket legend Sachin Tendulkar recently launched a research center on gastrointestinal and liver cancers after India defeated Australia by a…
SCB moots robotic surgeryThe New Indian ExpressWith the legislation of Anatomy Amendment Bill by the Assembly, SCB Medical College and Hospital, Cuttack has come up with new visions for adoption of Robot Assisted Surgery, Radio Surgery and LTx liver tr…
 Boston Globe |
India rejects plea against cancer drug
Boston Globe Last year, India’s patent office allowed local drug manufacturer Natco Pharma Ltd. to produce a generic version of Bayer’s kidney and liver cancer drug Nexavar on the grounds it would make the drug available to the public at a reasonably affordable price. Enter compulsory licensingBusiness Standard Indian patent appeal board upholds compulsory license on Bayer’s NexavarThe Pharma Letter IPAB rejects Bayer’s appeal on the grant of Compulsory LicenseLexology (registration) Morning Star Online –Newstalk ZB all 52 news articles » |
 Newstalk ZB |
Indian patent appeal board upholds compulsory license on Bayer’s Nexavar
The Pharma Letter … grant of a compulsory licence has now been issued by India’s Intellectual Property Appellate Board (IPAB) in Chennai, upholding the March 2012 granting of the first compulsory license for the firm’s kidney and liver cancer drug Nexavar (sorafenib … India rejects German transnational’s cancer drug patent appealMorning Star Online Landmark ruling against patent drugs in IndiaNewstalk ZB India Rejects Bayer Plea Against Cheap Cancer DrugPharmaceutical Processing |
|
‘Employees State Insurance should foot scribe’s liver transplant bill’
Times of India HYDERABAD: Lokayukta Justice B Subhashan Reddy on Tuesday directed the state medical commissioner of Employees State Insurance (ESI) scheme and the managing director of Global Hospital, Lakdi-ka-Pul, to perform liver transplantation on a scribe in … |
The HinduSachin bats for healthcareThe HinduLegendary batsman Sachin Tendulkar took time off to bat for healthcare on Tuesday and launched GIFT ( Gastrointestinal and Liver Foundation for Research & Treatment of Cancers), founded by a group of doct…
 Times LIVE |
India rejects Bayer plea against cheap cancer drug
Times LIVE … India’s patent office allowed local drug manufacturer Natco Pharma Ltd. to produce a generic version of Bayer’s kidney and liver cancer treatment Nexavar on the grounds that this would make the drug available to the public at a reasonably … Bayer loses plea against cheap Indian cancer drugHindustan Times Bayer fails to overturn Nexavar compulsory licence in IndiaPMLiVE Bayer loses appeal in Indian compulsory licence casePharmaTimes Reuters all 46 news articles » |
 The National Law Journal |
India board rules against Bayer in cancer drug patent case
Reuters Announcing the decision, Justice Prabha Sridevan said the kidney and liver cancer drug should be available at an affordable price to everybody. Bayer said in a statement it “strongly disagreed” with the conclusions of the board, adding that it would … India Patent Ruling on Cancer Drug a Blow to Bayer AGThe National Law Journal India Appeals Body Rejects Bayer’s Plea on NexavarWall Street Journal (India) Bayer to Appeal India Ruling That Allows Copy of Cancer DrugBloomberg Economic Times –Intellectual Property Watch –MSF UK (press release) all 19 news articles » |